Jerzy Jaroszewicz

List of Publications by Year in descending order

102 papers	3,814 citations	201674 27 h-index	138484 58 g-index
105 all docs	105 docs citations	105 times ranked	5476 citing authors

#	Article	IF	Citations
1	Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. Journal of Clinical Medicine, 2022, 11, 389.	2.4	2
2	High in-hospital and post-discharge mortality in patients with a pre-existing diagnosis of heart failure hospitalized due to COVID-19. Kardiologia Polska, 2022, 80, 90-92.	0.6	1
3	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. Vaccines, 2022, 10, 557.	4.4	15
4	Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication. Journal of Clinical Medicine, 2022, 11, 3044.	2.4	2
5	High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland. Archives of Medical Science, 2021, 17, 675-681.	0.9	3
6	Neurologic manifestations of COVID-19. Authorsâ€™ reply. Polish Archives of Internal Medicine, 2021, 131, 208-209.	0.4	0
7	SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. Clinical Neurology and Neurosurgery, 2021, 201, 106451.	1.4	13
8	Realâ€world effectiveness and safety of directâ€acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epiâ€Ter2 Study. Liver International, 2021, 41, 1789-1801.	3.9	10
9	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. Journal of Clinical Medicine, 2021, 10, 1583.	2.4	21
10	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, 487-496.	0.4	48
11	Acute Coronary Tree Thrombosis After Vaccination for COVID-19. JACC: Cardiovascular Interventions, 2021, 14, e103-e104.	2.9	46
12	Impact of Kidney Failure on the Severity of COVID-19. Journal of Clinical Medicine, 2021, 10, 2042.	2.4	13
13	Symptom-based early-stage differentiation between SARS-CoV-2 versus other respiratory tract infectionsâ€”Upper Silesia pilot study. Scientific Reports, 2021, 11, 13580.	3.3	5
14	Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study. Journal of Inflammation Research, 2021, Volume 14, 3359-3366.	3.5	17
15	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. Journal of Clinical Medicine, 2021, 10, 3280.	2.4	13
16	Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy. Cancers, 2021, 13, 3694.	3.7	16
17	Experimental and CFD Simulations of the Aerosol Flow in the Air Ventilating the Underground Excavation in Terms of SARS-CoV-2 Transmission. Energies, 2021, 14, 4743.	3.1	4
18	HCV resistance-associated substitutions following direct-acting antiviral therapy failure â€“ Real-life data from Poland. Infection, Genetics and Evolution, 2021, 93, 104949.	2.3	2

#	Article	IF	Citations
19	Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy. Clinical and Experimental Hepatology, 2021, 7, 117-124.	1.3	4
20	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. Polish Archives of Internal Medicine, 2021, 131, .	0.4	6
21	Screening Support System Based on Patient Survey Dataâ€"Case Study on Classification of Initial, Locally Collected COVID-19 Data. Applied Sciences (Switzerland), 2021, 11, 10790.	2.5	4
22	Realâ€world experience with Grazoprevir/Elbasvir in the treatment of previously â€œdifficult to treatâ€• patients infected with hepatitis C virus genotype 1 and 4. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1238-1246.	2.8	9
23	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naÃ¯ve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Advances in Medical Sciences, 2020, 65, 12-17.	2.1	5
24	Is an 8â€week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the realâ€world experience?. Journal of Gastroenterology and Hepatology (Australia), 2020, 36, 1944-1952.	2.8	9
25	Searching for the optimal population for hepatitis C virus screening in Poland. Clinical and Experimental Hepatology, 2020, 6, 74-76.	1.3	3
26	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Review of Anti-Infective Therapy, 2020, 18, 1045-1054.	4.4	12
27	Lymphocyte-To-Monocyte Ratio as the Best Simple Predictor of Bacterial Infection in Patients with Liver Cirrhosis. International Journal of Environmental Research and Public Health, 2020, 17, 1727.	2.6	33
28	High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	17
29	Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 269-274.	0.9	11
30	Changes of patient profile, treatment effectiveness and safety during 4 years access to interferon-free therapy for hepatitis C virus infection. Polish Archives of Internal Medicine, 2020, 130, 163-172.	0.4	14
31	Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. Polish Archives of Internal Medicine, 2020, 130, 352-357.	0.4	51
32	Annex #1 as of 8 June 2020 to: Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. Polish Archives of Internal Medicine, 2020, 130, 557-558.	0.4	20
33	Neurological symptoms as a clinical manifestation of COVID-19: implications for internists. Polish Archives of Internal Medicine, 2020, 131, 54-62.	0.4	11
34	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. Polish Archives of Internal Medicine, 2020, 130, 915-918.	0.4	30
35	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study. Polish Archives of Internal Medicine, 2020, 131, 103-110.	0.4	12
36	Clinical Usefulness of the Inhibitory Control Test (ICT) in the Diagnosis of Minimal Hepatic Encephalopathy. International Journal of Environmental Research and Public Health, 2020, 17, 3645.	2.6	5

#	Article	IF	Citations
37	Prophylaxis of hepatitis B virus (HBV) infection reactivation â€“ recommendations of the Working Group for prevention of HBV reactivation. Clinical and Experimental Hepatology, 2019, 5, 195-202.	1.3	22
38	Effect of comedication on ombitasvir/paritaprevir/ritonavir Â± dasabuvir Â± ribavirin therapy in chronic hepatitis C â€“ a real-world study. Clinical and Experimental Hepatology, 2019, 5, 215-223.	1.3	1
39	Soluble immune markers in the different phases of chronic hepatitis B virus infection. Scientific Reports, 2019, 9, 14118.	3.3	14
40	Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients. Clinical and Experimental Hepatology, 2019, 5, 75-80.	1.3	6
41	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-9.	1.9	12
42	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clinical Infectious Diseases, 2019, 69, 1969-1979.	5.8	21
43	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. Journal of Interferon and Cytokine Research, 2018, 38, 93-100.	1.2	9
44	siRNA drug development against hepatitis B virus infection. Expert Opinion on Biological Therapy, 2018, 18, 609-617.	3.1	27
45	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
46	Predictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patients. Clinical and Experimental Hepatology, 2018, 4, 240-246.	1.3	9
47	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC Infectious Diseases, 2018, 18, 580.	2.9	2
48	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clinical and Experimental Hepatology, 2018, 4, 153-157.	1.3	15
49	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. Hepatitis Monthly, 2018, 18, .	0.2	2
50	Surgical treatment of liver tumors â€“ own experience and literature review. Clinical and Experimental Hepatology, 2017, 1, 1-8.	1.3	8
51	The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. Clinical and Experimental Hepatology, 2017, 3, 127-134.	1.3	20
52	Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	9
53	Recommendations for the treatment of hepatitis B in 2017. Clinical and Experimental Hepatology, 2017, 2, 35-46.	1.3	15
54	Normalizing serum hepcidin but not Î±-1-antitrypsin level during effective treatment of chronic hepatitis C. Clinical and Experimental Hepatology, 2017, 4, 203-208.	1.3	2

#	Article	IF	Citations
55	Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.3	0
56	Hepatitis E virus infection--a new threat for Europe. Przeglad Epidemiologiczny, 2016, 70, 11-4, 103-6.	0.2	3
57	Review article Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection. Clinical and Experimental Hepatology, 2015, 2, 35-38.	1.3	8
58	Original article Distribution of HBV genotypes in Poland. Clinical and Experimental Hepatology, 2015, 1, 1-4.	1.3	9
59	Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatologii I Alergologii, 2015, 2, 101-106.	0.9	43
60	Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs, 2015, 24, 1229-1239.	4.1	23
61	Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. Hepatitis Monthly, 2015, 15, e27740.	0.2	13
62	Serum cytochrome c and m30â€neoepitope of cytokeratinâ€18 in chronic hepatitis C. Liver International, 2014, 34, 544-550.	3.9	27
63	A pill for <scp>HCV</scp> â€“ myth or foreseeable future?. Liver International, 2014, 34, 6-11.	3.9	20
64	Emerging treatments for hepatitis C. Expert Opinion on Emerging Drugs, 2013, 18, 461-475.	2.4	30
65	Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults. Cytokine, 2013, 64, 97-102.	3.2	13
66	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine, 2013, 61, 690.	3.2	3
67	Metabolic syndrome and hepatitis C infection â€“ brothers in arms. Liver International, 2013, 33, 1135-1137.	3.9	4
68	Interferon Î±â€“Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. Journal of Infectious Diseases, 2012, 205, 1351-1362.	4.0	38
69	Improved Immune Status Corresponds with Long-Term Decline of Quantitative Serum Hepatitis B Surface Antigen in HBV/HIV Co-infected Patients. Viral Immunology, 2012, 25, 442-447.	1.3	15
70	Update on alisporivir in treatment of viral hepatitis C. Expert Opinion on Investigational Drugs, 2012, 21, 375-382.	4.1	44
71	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology, 2012, 55, 695-708.	7.3	158
72	Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. PLoS ONE, 2012, 7, e43143.	2.5	42

#	Article	IF	Citations
73	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. Journal of Clinical Virology, 2011, 50, 292-296.	3.1	76
74	Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. Antiviral Therapy, 2011, 16, 915-924.	1.0	76
75	Hepatitis D virusâ€specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfaâ€treatment. Liver International, 2011, 31, 1395-1405.	3.9	42
76	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. PLoS Pathogens, 2011, 7, e1002045.	4.7	102
77	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. Journal of Hepatology, 2010, 52, 514-522.	3.7	355
78	Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine, 2010, 52, 225-229.	3.2	35
79	Interferon-Î±â€“Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 1885-1897.e10.	1.3	177
80	Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C. World Journal of Gastroenterology, 2010, 16, 1747.	3.3	15
81	Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regulatory Peptides, 2008, 147, 25-28.	1.9	68
82	Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment. Cytokine, 2008, 44, 14-17.	3.2	29
83	Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis. Biomarkers, 2008, 13, 478-485.	1.9	22
84	Pigment epithelium-derived factor in ulcerative colitis: Possible relationship with disease activity. Regulatory Peptides, 2007, 140, 1-4.	1.9	7
85	The influence of protease inhibitors on a frequency of lipid metabolism disturbances occurrence in HIV-1 infected patients. HIV and AIDS Review, 2007, 6, 19-23.	0.2	1
86	Slowly progressing cutaneous T-cell lymphoma in HIV infected individual. HIV and AIDS Review, 2007, 6, 33-35.	0.2	1
87	Serum concentrations of Î±-defensins in patients with different stages of HIV-infection. HIV and AIDS Review, 2007, 6, 20-22.	0.2	1
88	Specifically targeted antiviral therapy for hepatitis C virus. World Journal of Gastroenterology, 2007, 13, 5673.	3.3	46
89	Concentrations of Soluble Fas and Soluble Fas Ligand as Indicators of Programmed Cell Death among Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Viral Immunology, 2006, 19, 570-575.	1.3	5
90	Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antiviral Therapy, 2006, 11, 641-5.	1.0	7

#	Article	IF	Citations
91	Does Haart Improve Renal Function? An Association between Serum Cystatin C Concentration, HIV Viral Load and Haart Duration. Antiviral Therapy, 2006, 11, 641-646.	1.0	23
92	Acute Hepatitis E Complicated by Acute Pancreatitis. Pancreas, 2005, 30, 382-384.	1.1	46
93	Plasma transforming growth factor Î²1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B. Regulatory Peptides, 2005, 131, 54-58.	1.9	6
94	Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland. World Journal of Gastroenterology, 2005, 11, 2630.	3.3	39
95	Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World Journal of Gastroenterology, 2005, 11, 400.	3.3	30
96	Plasma interleukin-18 reflects severity of ulcerative colitis. World Journal of Gastroenterology, 2005, 11, 605.	3.3	31
97	Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-Î²1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World Journal of Gastroenterology, 2005, 11, 6833.	3.3	8
98	Specific ssDNA concentration in liver tissue as an index of apoptosis in hepatitis C virus-infected patients. World Journal of Gastroenterology, 2005, 11, 6130.	3.3	1
99	Increased Plasma Transforming Growth Factor-Î²1 Is Associated with Disease Progression in HIV-1-Infected Patients. Viral Immunology, 2004, 17, 109-113.	1.3	63
100	Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes and Infection, 2004, 6, 1273-1277.	1.9	30
101	Effect of lamivudine treatment on plasma levels of transforming growth factor Î²1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World Journal of Gastroenterology, 2004, 10, 2661.	3.3	11
102	Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 as biomarkers of ulcerative colitis activity. World Journal of Gastroenterology, 2003, 9, 2843.	3.3	42